**Novo Nordisk Launches Wegovy Pill for Weight Loss in the U.S.**
Novo Nordisk has officially introduced the oral version of its weight-loss medication, Wegovy, in the United States as of Monday. Following the success of GLP-1 (Glucagon-Like Peptide-1) drugs such as Ozempic and Wegovy, the new pill format is now available for consumers. Approved by the U.S. Food and Drug Administration in December 2025, this launch is a strategic move for Novo Nordisk as it seeks to reclaim market share from competitor Eli Lilly, which is expected to receive approval for its own weight-loss pill, Mounjaro, around March 2026.
The Wegovy pill will be offered in two higher doses of 9 mg and 25 mg, both priced at $299 for a month’s supply. The lower 4 mg dose will increase to $199 starting April 15, according to the company’s official information. This new oral option is anticipated to attract a broader customer base, particularly those who prefer not to use injectable medications.
Internationally, regulators are also assessing the Wegovy pill, with UK approval expected by late 2026, as reported by Reuters. Following the launch, Novo Nordisk’s shares experienced a positive response, with a 5% increase in its Denmark-listed stock and a 4.6% rise in its U.S. shares. In contrast, Eli Lilly’s stock saw a decline of 3.5% during afternoon trading.
The success of the Wegovy pill will largely depend on Novo Nordisk’s ability to attract cash-paying customers, diverging from the traditional model where drug prices are often managed through health insurance. The medication will be accessible at major U.S. pharmacies, including Costco and CVS, as well as through telehealth providers like Ro, LifeMD, WeightWatchers, GoodRx, and NovoCare Pharmacy.
The Wegovy pill, containing semaglutide—the same active ingredient found in its popular injectable treatments—will start with a 1.5 mg dose. Novo Nordisk also markets a 1.5 mg oral semaglutide option for type 2 diabetes under the name Rybelsus. The remaining doses of the Wegovy pill are expected to be available to patients by the end of this week.
In conclusion, the launch of the Wegovy pill marks a significant development in the weight-loss medication market, offering consumers a new, flexible option while positioning Novo Nordisk to enhance its competitive edge.
**FAQ**
**What is Wegovy and how does it work?**
Wegovy is an oral weight-loss medication that contains semaglutide, designed to help individuals manage their weight by reducing appetite and increasing feelings of fullness.
